{"id":8607,"date":"2025-08-25T16:06:50","date_gmt":"2025-08-25T08:06:50","guid":{"rendered":"https:\/\/regask.com\/?p=8607"},"modified":"2025-09-02T16:42:46","modified_gmt":"2025-09-02T08:42:46","slug":"parkinson-krankheit-7b-markt-2033-regulatorische-auswirkungen","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/parkinsons-disease-7b-market-2033-regulatory-impact\/","title":{"rendered":"$7 Milliarden Markt f\u00fcr Parkinson-Krankheit bis 2033: Implizite\u2026"},"content":{"rendered":"<p><span class=\"TextRun MacChromeBold SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW227341056 BCX0\">On <strong>August 5, 2025<\/strong><\/span><\/span><span class=\"TextRun SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW227341056 BCX0\">, <\/span><\/span><a class=\"Hyperlink SCXW227341056 BCX0\" href=\"https:\/\/www.clinicaltrialsarena.com\/about-us\/#:~:text=Clinicaltrialsarena.com%20covers%20every%20aspect%20of%20the%20drug%20development,with%20the%20latest%20and%20most%20significant%20industry%20developments.\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"TextRun Underlined SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW227341056 BCX0\" data-ccp-charstyle=\"Hyperlink\">Clinical Trials Arena<\/span><\/span><\/a><span class=\"TextRun SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW227341056 BCX0\"> released a market forecast detailing significant growth in <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW227341056 BCX0\">Parkinson\u2019s disease (PD) therapeutics<\/span><\/span><\/strong><span class=\"TextRun SCXW227341056 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW227341056 BCX0\"> across seven major markets (U.S., France, Germany, Italy, Spain, U.K., and Japan). The report outlines expected drug launches, persistent development challenges, and the factors driving market expansion over the next decade.<\/span><\/span><span class=\"EOP SCXW227341056 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<div class=\"row\"  id=\"row-1400761770\">\n\n\t<div id=\"col-213474876\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3><span class=\"TextRun MacChromeBold SCXW121722936 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW121722936 BCX0\" data-ccp-parastyle=\"heading 3\">Market Overview and Growth Drivers<\/span><\/span><\/h3>\n\t<div id=\"gap-940191646\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-940191646 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>The PD therapeutics market<\/strong> is projected to grow at a <strong>compound annual growth rate (CAGR) of 7.6%<\/strong>, reaching <strong>$7 billion by 2033<\/strong> in the seven major markets. This growth is fueled by <strong>eight late-stage<\/strong> pipeline products anticipated to be launched during the forecast period, addressing both <strong>motor symptoms and disease modification.\u00a0<\/strong><\/p>\n<p><b><span data-contrast=\"auto\">Symptomatic treatments<\/span><\/b><span data-contrast=\"auto\"> for motor symptoms expected to drive sales include:<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">NeuroDerm\u2019s ND-0612<\/span><\/b><span data-contrast=\"auto\"> (carbidopa + levodopa)<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">AbbVie\u2019s tavapadon<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Pharma Two B\u2019s P2B001<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Cerevance\u2019s solengepras<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"5\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">PharmaTher Holdings\u2019 Ketarx<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">Together, these products are forecast to contribute <\/span><b><span data-contrast=\"auto\">$1.6 billion<\/span><\/b><span data-contrast=\"auto\"> in sales by 2033.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Non-motor symptom treatments<\/span><\/b><span data-contrast=\"auto\"> are less represented, with <\/span><b><span data-contrast=\"auto\">Anavex\u2019s blarcamesine<\/span><\/b><span data-contrast=\"auto\"> as the sole late-stage therapy targeting conditions such as PD dementia. Other candidates in this category have been discontinued due to development challenges.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Disease-modifying therapies (DMTs)<\/span><\/b><span data-contrast=\"auto\"> targeting <\/span><b><span data-contrast=\"auto\">\u03b1-synuclein aggregates<\/span><\/b><span data-contrast=\"auto\"> include <\/span><b><span data-contrast=\"auto\">Roche\u2019s prasinezumab<\/span><\/b><span data-contrast=\"auto\"> and <\/span><b><span data-contrast=\"auto\">Annovis Bio\u2019s buntanetap<\/span><\/b><span data-contrast=\"auto\">. While pivotal trial results have been<\/span><\/p>\n<p><span data-contrast=\"auto\">mixed, exploratory data suggests potential <\/span><b><span data-contrast=\"auto\">neuroprotective benefits<\/span><\/b><span data-contrast=\"auto\">. Combined sales for these DMTs are projected to reach <\/span><b><span data-contrast=\"auto\">$597.5 million globally<\/span><\/b><span data-contrast=\"auto\"> by 2033.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Cell therapy innovations<\/span><\/b><span data-contrast=\"auto\"> are also advancing. <\/span><b><span data-contrast=\"auto\">BlueRock Therapeutics\u2019 bemdaneprocel<\/span><\/b><span data-contrast=\"auto\">, currently in <\/span><b><span data-contrast=\"auto\">Phase III trials (exPDite-2 [NCT06944522])<\/span><\/b><span data-contrast=\"auto\">, involves the transplantation of dopaminergic neuronal progenitor stem cells into the brain, aiming to halt disease progression.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Although <\/span><b><span data-contrast=\"auto\">patent expirations<\/span><\/b><span data-contrast=\"auto\"> for key branded drugs may lead to increased generic competition, new product launches are expected to counterbalance market erosion and sustain growth.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-213474876 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2107426872\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3><span class=\"TextRun MacChromeBold SCXW121722936 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW121722936 BCX0\" data-ccp-parastyle=\"heading 3\">Why It Matters<\/span><\/span><\/h3>\n\t<div id=\"gap-1522645805\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1522645805 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\">This forecast reflects a <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\">robust innovation cycle<\/span><\/span><\/strong><span class=\"TextRun SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\"> in neurology, signaling opportunities for <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\">CNS drug developers<\/span><\/span><\/strong><span class=\"TextRun SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\"> to expand <\/span><span class=\"NormalTextRun SCXW255455567 BCX0\">their portfolios<\/span><span class=\"NormalTextRun SCXW255455567 BCX0\">. The growing focus on <\/span><\/span><span class=\"TextRun MacChromeBold SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\">disease modification<\/span><\/span><span class=\"TextRun SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\"> and <\/span><\/span><span class=\"TextRun MacChromeBold SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255455567 BCX0\">cell-based approaches<\/span><\/span><span class=\"TextRun SCXW255455567 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"> <span class=\"NormalTextRun SCXW255455567 BCX0\">represents<\/span><span class=\"NormalTextRun SCXW255455567 BCX0\"> a shift toward treatments that go beyond symptom management, potentially improving long-term outcomes for PD patients.<\/span><\/span><span class=\"EOP SCXW255455567 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2107426872 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-623997027\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3><span class=\"TextRun MacChromeBold SCXW247177418 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW247177418 BCX0\" data-ccp-parastyle=\"heading 3\">Relevant Stakeholders<\/span><\/span><span class=\"EOP SCXW247177418 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h3>\n\t<div id=\"gap-1519776053\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1519776053 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">This update is particularly relevant for <\/span><\/span><span class=\"TextRun MacChromeBold SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\"><strong>regulatory affairs teams<\/strong><\/span><\/span><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">, <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">commercial strategists<\/span><\/span><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">, <\/span><\/span><span class=\"TextRun MacChromeBold SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">business development executives<\/span><\/span><\/strong><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\"><strong>,<\/strong> and <\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">R&amp;D teams<\/span><\/span><\/strong><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\"> engaged in <\/span><\/span><span class=\"TextRun MacChromeBold SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\"><strong>neurology<\/strong> and <strong>CNS drug development<\/strong><\/span><\/span><strong><span class=\"TextRun SCXW65340671 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW65340671 BCX0\">.<\/span><\/span><span class=\"EOP SCXW65340671 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-623997027 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-553442577\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Next Steps<\/h3>\n\t<div id=\"gap-846635346\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-846635346 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Stakeholders should monitor the progress of late-stage candidates, competitive launches, and key patent expirations to inform <strong>long-term positioning strategies<\/strong>. Engagement in <strong>research collaborations<\/strong> and readiness for <strong>licensing or partnership opportunities<\/strong> may provide strategic advantage as the market evolves. While keeping track of market dynamics is essential, navigating the complex and fast-changing regulatory environment requires equally robust support.<\/p>\n<p><a class=\"Hyperlink SCXW237182428 BCX0\" href=\"https:\/\/regask.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"TextRun Underlined MacChromeBold SCXW237182428 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW237182428 BCX0\" data-ccp-charstyle=\"Hyperlink\">RegASK<\/span><\/span><\/a> <span class=\"TextRun SCXW237182428 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW237182428 BCX0\">is<\/span><span class=\"NormalTextRun SCXW237182428 BCX0\"> an<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW237182428 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW237182428 BCX0\"> AI-driven Agentic Solution for Regulatory Intelligence and Workflow Orchestration<\/span><\/span><\/strong><span class=\"TextRun SCXW237182428 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW237182428 BCX0\"> that helps <\/span><\/span><span class=\"TextRun SCXW237182428 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW237182428 BCX0\"><strong>life sciences<\/strong> and <strong>pharmaceutical<\/strong> companies stay ahead of <\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">constantly changing regulations<\/span><span class=\"NormalTextRun SCXW237182428 BCX0\"> through<\/span> <span class=\"NormalTextRun SCXW237182428 BCX0\">timely<\/span> <span class=\"NormalTextRun SCXW237182428 BCX0\">global regulatory <\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">monitoring, <\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">s<\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">mart documentation, curated <\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">alerts<\/span> <span class=\"NormalTextRun SCXW237182428 BCX0\">and compliance insights<\/span><span class=\"NormalTextRun SCXW237182428 BCX0\">. <\/span><\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-553442577 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1501651239\">\n\n\t<div id=\"col-1697074830\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" ><\/div>\n<h3>FAQs<\/h3>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1697074830 > .col-inner {\n  margin: 0px 0px -10px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1129689329\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-691429869\" class=\"text\">\n\t\t\n<h4><strong>What is the projected CAGR of the Parkinson\u2019s disease market in the seven major markets?<\/strong><\/h4>\n\t\t\n<style>\n#text-691429869 {\n  line-height: 2.1;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-2102112861\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2102112861 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW180666047 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW180666047 BCX0\"> The market is projected to grow at a <\/span><\/span><span class=\"TextRun MacChromeBold SCXW180666047 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW180666047 BCX0\">CAGR of 7.6%<\/span><\/span><span class=\"TextRun SCXW180666047 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW180666047 BCX0\">, reaching <\/span><span class=\"NormalTextRun SCXW180666047 BCX0\">$7 billion<\/span><span class=\"NormalTextRun SCXW180666047 BCX0\"> by 2033.<\/span><\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1129689329 > .col-inner {\n  margin: 0px 0px 0px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-995005009\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-836113181\" class=\"text\">\n\t\t\n<h4><span class=\"LineBreakBlob BlobObject DragDrop SCXW26426554 BCX0\"><strong><span class=\"TextRun MacChromeBold SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\">Which late-stage therapies are targeting \u03b1-synuclein aggregates?<\/span><\/span><span class=\"SCXW26426554 BCX0\">\u00a0<\/span><\/strong><br class=\"SCXW26426554 BCX0\" \/><\/span><\/h4>\n\t\t\n<style>\n#text-836113181 {\n  line-height: 2.1;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-771739863\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-771739863 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun MacChromeBold SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\">Roche\u2019s <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW26426554 BCX0\">prasinezumab<\/span><\/span><span class=\"TextRun SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\"> and <\/span><\/span><span class=\"TextRun MacChromeBold SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\">Annovis Bio\u2019s <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW26426554 BCX0\">buntanetap<\/span><\/span><span class=\"TextRun SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\"> are the two primary late-stage therapies targeting \u03b1-synuclein aggregates.<\/span><\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-995005009 > .col-inner {\n  margin: 0px 0px 0px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2064047403\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-1837949970\" class=\"text\">\n\t\t\n<h4><span class=\"LineBreakBlob BlobObject DragDrop SCXW26426554 BCX0\"><strong><span class=\"TextRun MacChromeBold SCXW26426554 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW26426554 BCX0\"><span class=\"NormalTextRun SCXW3537841 BCX0\">What is the current trial status of <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW3537841 BCX0\">BlueRock<\/span><span class=\"NormalTextRun SCXW3537841 BCX0\"> Therapeutics\u2019 <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW3537841 BCX0\">bemdaneprocel<\/span><span class=\"NormalTextRun SCXW3537841 BCX0\">?<\/span><\/span><\/span><\/strong><br class=\"SCXW26426554 BCX0\" \/><\/span><\/h4>\n\t\t\n<style>\n#text-1837949970 {\n  line-height: 2.1;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-507620770\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-507620770 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW48475876 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW48475876 BCX0\">Bemdaneprocel<\/span><span class=\"NormalTextRun SCXW48475876 BCX0\"> is in <\/span><\/span><span class=\"TextRun MacChromeBold SCXW48475876 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW48475876 BCX0\">Phase III trials (exPDite-2 [NCT06944522])<\/span><\/span><span class=\"TextRun SCXW48475876 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW48475876 BCX0\"> and is being investigated as a cell therapy for Parkinson\u2019s disease.<\/span><\/span><span class=\"EOP SCXW48475876 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2064047403 > .col-inner {\n  margin: 0px 0px 0px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Am 5. August 2025 ver\u00f6ffentlichte Clinical Trials Arena eine Marktprognose, die ein signifikantes Wachstum bei Parkinson-Therapeutika (PD) in sieben wichtigen M\u00e4rkten (USA, Frankreich, Deutschland, Italien, Spanien, Gro\u00dfbritannien und Japan) beschreibt. Der Bericht beschreibt die erwarteten Markteinf\u00fchrungen von Medikamenten, anhaltende Entwicklungsherausforderungen und die Faktoren, die das Marktwachstum im n\u00e4chsten Jahrzehnt vorantreiben.\u00a0<\/p>","protected":false},"author":32,"featured_media":8608,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[529,527,33,35],"tags":[],"class_list":["post-8607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe","category-united-states-regulations","category-news","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>$7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope | RegASK<\/title>\n<meta name=\"description\" content=\"The Parkinson\u2019s disease therapeutics market is projected to reach $7B by 2033 across seven major markets, driven by late-stage drug launches, disease-modifying therapies, and cell-based innovations. | $7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/parkinson-krankheit-7b-markt-2033-regulatorische-auswirkungen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope\" \/>\n<meta property=\"og:description\" content=\"The Parkinson\u2019s disease therapeutics market is projected to reach $7B by 2033 across seven major markets, driven by late-stage drug launches, disease-modifying therapies, and cell-based innovations. | $7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/parkinson-krankheit-7b-markt-2033-regulatorische-auswirkungen\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T08:06:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-02T08:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"$7 Billion Parkinson\u2019s Disease Market by 2033: Implic&hellip;\",\"datePublished\":\"2025-08-25T08:06:50+00:00\",\"dateModified\":\"2025-09-02T08:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/\"},\"wordCount\":664,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png\",\"articleSection\":[\"Europe &amp; Central Asia\",\"United States\",\"Regulatory News\",\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/\",\"name\":\"$7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png\",\"datePublished\":\"2025-08-25T08:06:50+00:00\",\"dateModified\":\"2025-09-02T08:42:46+00:00\",\"description\":\"The Parkinson\u2019s disease therapeutics market is projected to reach $7B by 2033 across seven major markets, driven by late-stage drug launches, disease-modifying therapies, and cell-based innovations. | $7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/parkinsons-disease-7b-market-2033-regulatory-impact\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png\",\"width\":800,\"height\":600,\"caption\":\"Parkinsons Disease Market Expected Reach 7 Billion 2033 Seven Major Markets\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"$7 Milliarden Parkinson-Markt bis 2033: Auswirkungen auf den Regulierungsumfang | RegASK","description":"Der Markt f\u00fcr Parkinson-Therapeutika wird Prognosen zufolge bis 2033 in sieben gro\u00dfen M\u00e4rkten $7B erreichen, angetrieben durch die Markteinf\u00fchrung von Medikamenten im Sp\u00e4tstadium, krankheitsmodifizierende Therapien und zellbasierte Innovationen. | $7 Milliarden Markt f\u00fcr Parkinson bis 2033: Auswirkungen auf den regulatorischen Umfang","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/parkinson-krankheit-7b-markt-2033-regulatorische-auswirkungen\/","og_locale":"de_DE","og_type":"article","og_title":"$7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope","og_description":"The Parkinson\u2019s disease therapeutics market is projected to reach $7B by 2033 across seven major markets, driven by late-stage drug launches, disease-modifying therapies, and cell-based innovations. | $7 Billion Parkinson\u2019s Disease Market by 2033: Implications for Regulatory Scope","og_url":"https:\/\/regask.com\/de\/parkinson-krankheit-7b-markt-2033-regulatorische-auswirkungen\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-08-25T08:06:50+00:00","article_modified_time":"2025-09-02T08:42:46+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/#article","isPartOf":{"@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"$7 Billion Parkinson\u2019s Disease Market by 2033: Implic&hellip;","datePublished":"2025-08-25T08:06:50+00:00","dateModified":"2025-09-02T08:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/"},"wordCount":664,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png","articleSection":["Europe &amp; Central Asia","United States","Regulatory News","Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/","url":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/","name":"$7 Milliarden Parkinson-Markt bis 2033: Auswirkungen auf den Regulierungsumfang | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png","datePublished":"2025-08-25T08:06:50+00:00","dateModified":"2025-09-02T08:42:46+00:00","description":"Der Markt f\u00fcr Parkinson-Therapeutika wird Prognosen zufolge bis 2033 in sieben gro\u00dfen M\u00e4rkten $7B erreichen, angetrieben durch die Markteinf\u00fchrung von Medikamenten im Sp\u00e4tstadium, krankheitsmodifizierende Therapien und zellbasierte Innovationen. | $7 Milliarden Markt f\u00fcr Parkinson bis 2033: Auswirkungen auf den regulatorischen Umfang","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/parkinsons-disease-7b-market-2033-regulatory-impact\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/08\/parkinsons-disease-market-expected-reach-7-billion-2033-seven-major-markets.png","width":800,"height":600,"caption":"Parkinsons Disease Market Expected Reach 7 Billion 2033 Seven Major Markets"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Intelligentere Regulierungsentscheidungen erm\u00f6glichen","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/8607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=8607"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/8607\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/8608"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=8607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=8607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=8607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}